Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting

被引：8
|
作者：
Hou, Jiangxue [1 ,2 ]
Li, Yufu [1 ,2 ]
Lin, Quande [1 ,2 ]
机构：
[1] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou 450008, Peoples R China
[2] Henan Canc Hosp, Zhengzhou 450008, Peoples R China
来源：
EXPERIMENTAL HEMATOLOGY & ONCOLOGY | 2023年 / 12卷 / 01期
关键词：
Multiple myeloma; Bispecific antibody; CAR T; Clinical trial;
D O I：
10.1186/s40164-023-00436-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Bispecific antibodies (BsAbs) and dual-targeted chimeric antigen receptor T (CAR T) cells have been employed in relapsed/refractory multiple myeloma (RRMM) patients over the past few years, as an increasing number of patients were ineffectively treated by >= 3 prior lines of therapy. BCMA/CD3 and GPRC5D/CD3 are the most popular combinations. Clinical findings indicated that patients exhibit a greater susceptibility to stronger and more enduring responses. Here, we summarize the latest data from the 2023 ASCO annual meeting on BsAbs targeting BCMA/CD3, GPRC5D/CD3 and BCMA/CD19 CAR T cells.
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting
    Guo, Ruiting
    Lu, Wenyi
    Zhang, Yi
    Cao, Xinping
    Jin, Xin
    Zhao, Mingfeng
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [22] A new era in myeloma: the advent of chimeric antigen receptor-T (CAR-T) cells and bispecific antibodies
    Ho, P. Joy
    Li, Eric W.
    INTERNAL MEDICINE JOURNAL, 2025,
  • [23] Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
    Sun, Fumou
    Cheng, Yan
    Wanchai, Visanu
    Guo, Wancheng
    Mery, David
    Xu, Hongwei
    Gai, Dongzheng
    Siegel, Eric
    Bailey, Clyde
    Ashby, Cody
    Al Hadidi, Samer
    Schinke, Carolina
    Thanendrarajan, Sharmilan
    Ma, Yupo
    Yi, Qing
    Orlowski, Robert Z.
    Zangari, Maurizio
    van Rhee, Frits
    Janz, Siegfried
    Bishop, Gail
    Tricot, Guido
    Shaughnessy, John D.
    Zhan, Fenghuang
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [24] Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
    Fumou Sun
    Yan Cheng
    Visanu Wanchai
    Wancheng Guo
    David Mery
    Hongwei Xu
    Dongzheng Gai
    Eric Siegel
    Clyde Bailey
    Cody Ashby
    Samer Al Hadidi
    Carolina Schinke
    Sharmilan Thanendrarajan
    Yupo Ma
    Qing Yi
    Robert Z. Orlowski
    Maurizio Zangari
    Frits van Rhee
    Siegfried Janz
    Gail Bishop
    Guido Tricot
    John D. Shaughnessy
    Fenghuang Zhan
    Nature Communications, 15
  • [25] Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
    Golubovskaya, Vita
    Zhou, Hua
    Li, Feng
    Berahovich, Robert
    Sun, Jinying
    Valentine, Michael
    Xu, Shirley
    Harto, Hizkia
    Sienkiewicz, John
    Huang, Yanwei
    Wu, Lijun
    BIOMEDICINES, 2021, 9 (10)
  • [26] Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
    Larson, Rebecca C.
    Kann, Michael C.
    Graham, Charlotte
    Mount, Christopher W.
    Castano, Ana P.
    Lee, Won-Ho
    Bouffard, Amanda A.
    Takei, Hana N.
    Almazan, Antonio J.
    Scarfo, Irene
    Berger, Trisha R.
    Schmidts, Andrea
    Frigault, Matthew J.
    Gallagher, Kathleen M. E.
    Maus, Marcela V.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [27] Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
    Rebecca C. Larson
    Michael C. Kann
    Charlotte Graham
    Christopher W. Mount
    Ana P. Castano
    Won-Ho Lee
    Amanda A. Bouffard
    Hana N. Takei
    Antonio J. Almazan
    Irene Scarfó
    Trisha R. Berger
    Andrea Schmidts
    Matthew J. Frigault
    Kathleen M. E. Gallagher
    Marcela V. Maus
    Nature Communications, 14
  • [28] Bispecific T cell engagers targeting CD20/CD3 in B-cell lymphoma: latest updates from 2023 EHA annual meeting
    Jin, Shenhe
    Liu, Yi
    Zhang, Ye
    Zhou, Fengping
    You, Liangshun
    Zhang, Jin
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2023, 14
  • [29] A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
    Mei, Heng
    Li, Chenggong
    Jiang, Huiwen
    Zhao, Xinying
    Huang, Zhiping
    Jin, Dan
    Guo, Tao
    Kou, Haiming
    Liu, Lin
    Tang, Lu
    Yin, Ping
    Wang, Zhihui
    Ai, Lisha
    Ke, Sha
    Xia, Yimeng
    Deng, Jun
    Chen, Lei
    Cai, Li
    Sun, Chunyan
    Xia, Linghui
    Hua, Gaoquan
    Hu, Yu
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [30] A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
    Heng Mei
    Chenggong Li
    Huiwen Jiang
    Xinying Zhao
    Zhiping Huang
    Dan Jin
    Tao Guo
    Haiming Kou
    Lin Liu
    Lu Tang
    Ping Yin
    Zhihui Wang
    Lisha Ai
    Sha Ke
    Yimeng Xia
    Jun Deng
    Lei Chen
    Li Cai
    Chunyan Sun
    Linghui Xia
    Gaoquan Hua
    Yu Hu
    Journal of Hematology & Oncology, 14
12345